Edesa Biotech Inc
NASDAQ:EDSA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Edesa Biotech Inc
NASDAQ:EDSA
|
CA |
|
Nan Ya Printed Circuit Board Corp
TWSE:8046
|
TW |
|
S
|
Steep Hill Inc
CNSX:STPH
|
CA |
|
Fuji Electric Co Ltd
TSE:6504
|
JP |
|
Jiayou International Logistics Co Ltd
SSE:603871
|
CN |
|
B
|
Bank Raya Indonesia Tbk PT
XBER:0R8
|
ID |
|
Shenyang Yuanda Intellectual Industry Group Co Ltd
SZSE:002689
|
CN |
|
L
|
Leon Fuat Bhd
KLSE:LEONFB
|
MY |
|
M
|
Montnets Cloud Technology Group Co Ltd
SZSE:002123
|
CN |
|
N
|
Nature Wood Group Ltd
NASDAQ:NWGL
|
MO |
|
Agree Realty Corp
NYSE:ADC
|
US |
|
S
|
SFP Tech Holdings Bhd
KLSE:SFPTECH
|
MY |
|
D
|
Daeryuk Can Co Ltd
KOSDAQ:004780
|
KR |
|
Oxford Square Capital Corp
NASDAQ:OXSQ
|
US |
|
Yunnan Yuntianhua Co Ltd
SSE:600096
|
CN |
|
N
|
Nissui Corp
SWB:71N
|
JP |
|
L
|
Lian Beng Group Ltd
SGX:L03
|
SG |
|
Amsterdam Commodities NV
OTC:ACNFF
|
NL |
|
Cambridge Technology Enterprises Ltd
NSE:CTE
|
IN |
|
W
|
Wodkan Przedsiebiorstwo Wodociagow i Kanalizacji SA
WSE:WOD
|
PL |
|
Wynnstay Properties PLC
LSE:WSP
|
UK |
|
Esprinet SpA
MIL:PRT
|
IT |
|
C
|
Clas Ohlson AB
SWB:OHCB
|
SE |
|
Parkit Enterprise Inc
XTSX:PKT
|
CA |
Edesa Biotech Inc
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. The company is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. The company is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. The company is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. The company is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.
